Country: United States
Language: English
Source: NLM (National Library of Medicine)
ESTRADIOL (UNII: 4TI98Z838E) (ESTRADIOL - UNII:4TI98Z838E)
Padagis Israel Pharmaceuticals Ltd
ESTRADIOL
ESTRADIOL 0.1 mg in 1 g
VAGINAL
PRESCRIPTION DRUG
Estradiol Vaginal Cream, 0.01% is indicated in the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. Estradiol Vaginal Cream, 0.01% should not be used in women with any of the following conditions:
Estradiol Vaginal Cream USP, 0.01% NDC 45802-097-35: Tube containing 1½ oz (42.5 g) with a calibrated plastic applicator for delivery of 1, 2, 3, or 4 g. Store at room temperature 20° to 25°C (68° to 77°F). Protect from temperatures in excess of 40°C (104°F). Keep Estradiol Vaginal Cream, 0.01% out of the reach of children. REFERENCES Manufactured by Padagis® Yeruham, Israel www.padagis.com Rev 02-24 4H700 RC PH4
Abbreviated New Drug Application
ESTRADIOL VAGINAL- ESTRADIOL CREAM PADAGIS ISRAEL PHARMACEUTICALS LTD ---------- ESTRADIOL VAGINAL CREAM USP, 0.01% RX ONLY WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA ESTROGEN-ALONE THERAPY ENDOMETRIAL CANCER There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see WARNINGS, MALIGNANT NEOPLASMS, ENDOMETRIAL CANCER]. CARDIOVASCULAR DISORDERS AND PROBABLE DEMENTIA Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia [see CLINICAL STUDIES and WARNINGS, CARDIOVASCULAR DISORDERS, and PROBABLE DEMENTIA]. The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg]-alone, relative to placebo [see CLINICAL STUDIES and WARNINGS, CARDIOVASCULAR DISORDERS]. The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see CLINICAL STUDIES and WARNINGS, PROBABLE DEMENTIA and PRECAUTIONS, GERIATRIC USE]. In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens. Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest du Read the complete document